HERmark Presents Assay Results In Metastatic Breast Cancer

[tousled1]

Monogram Biosciences presented the results of a study detailing the HERmark Assay's ability to identify metastatic breast cancer patients who are most likely to respond to Herceptin

full article: http://www.emaxhealth.com/98/19118.html